Please Wait.....
Report
Global Generic Drugs Market Report and Forecast 2023-2031
Market Report I 2023-05-06 I 147 Pages I EMR Inc.
Global Generic Drug Market Report and Forecast 2023-2031
Global Generic Drugs Market Outlook
The global generic drugs market value was USD 411.8 billion in 2022, driven by the increasing demand for affordable medications across the globe. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to achieve a value of USD 666.8 billion by 2031.
Generic Drugs Introduction
Generic drugs are pharmaceutical products that have the same active ingredients, dosage form, strength, and route of administration as the branded drugs. They are developed and marketed after the patent expiry of the original branded drugs. The production and sale of generic drugs are usually much cheaper than their branded counterparts, making them an affordable option for patients.
The global generic drug market has witnessed steady growth over the years due to various factors such as the increasing prevalence of chronic diseases, the rise in the aging population, and the cost-effectiveness of these drugs. In addition, the patent expiry of several branded drugs has resulted in an increase in the number of generic drug approvals by regulatory bodies, further propelling market growth.
However, the market also faces challenges such as a lack of awareness about generic drugs in some regions, stringent regulatory policies, and the presence of counterfeit products. Nevertheless, ongoing research and development activities aimed at improving the safety and efficacy of generic drugs are expected to open up new growth opportunities for the market in the future.
Generic Drugs Market Scenario
Generic drugs are pharmaceuticals that have the same active ingredients, dosage, and strength as their brand-name counterparts, but are sold under their chemical name rather than a brand name. Generic drugs are typically less expensive than brand-name drugs and are considered a cost-effective alternative for patients who require ongoing medication therapy. The global market for generic drugs has been growing rapidly in recent years, driven by factors such as rising healthcare costs, increasing demand for affordable medications, and expiration of patents on branded drugs.
The market for generic drugs is highly competitive, with a large number of players operating in the space. Many pharmaceutical companies have entered the market to capitalize on the growing demand for generic drugs, resulting in increased competition and pricing pressures. The market is also characterized by ongoing efforts to improve manufacturing processes and reduce costs, as well as increasing regulatory scrutiny to ensure the safety and quality of generic drugs.
In addition, there is growing interest in the development of complex generic drugs, such as biosimilars, which are highly similar to biologic drugs and have the potential to offer significant cost savings to patients. The increasing focus on specialty drugs and the development of complex generics is expected to drive further growth in the global generic drug market in the coming years.
Generic Drugs Market Segmentations
Market Breakup by Brand
- Pure Generic
- Branded Generic
Market Breakup by Indications
- Central Nervous System (CNS)
- Cardiovascular
- Dermatology
- Oncology
- Respiratory
- Others
Market Breakup by Route of Administration
- Oral
- Topical
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Centers
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the Generic Drugs Market
Some key trends in the generic drug market are:
- Increasing demand for cost-effective drugs: The rising healthcare expenditure is driving the demand for generic drugs, which are more affordable than branded drugs. As governments and insurance companies push for cost-effective alternatives, the demand for generic drugs is expected to increase.
- Patent expirations: As patents for major branded drugs expire, it provides an opportunity for generic drug manufacturers to enter the market. The loss of exclusivity allows generic drug manufacturers to produce and market a cheaper version of the drug, leading to increased competition.
- Growth in the biologics market: Biologic drugs, which are more complex and expensive to manufacture, are now facing patent expirations. This presents an opportunity for generic drug manufacturers to enter the market and offer more affordable alternatives.
- Regulatory changes: Government regulations around the world are pushing for more widespread use of generic drugs, which is expected to increase demand. For example, the FDA has launched initiatives to expedite the review process for generic drugs, making it easier for them to enter the market.
- Increasing consolidation: The generic drug market has seen increasing consolidation, with larger companies acquiring smaller ones to increase their market share. This trend is expected to continue, with larger companies seeking to expand their portfolios and global presence.
Generic Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceuticals Industries Ltd.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Fresenius SE & Co. KGaA
- Lupin
- Endo International plc.
- Aurobindo Pharma
- Novartis AG
- Hikma Pharmaceuticals PLC.
- STADA Arzneimittel AG
13. Eli Lilly and Company
14. Aspen Holdings
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Generic Drug Market Overview
3.1 Global Generic Drug Market Historical Value (2016-2022)
3.2 Global Generic Drug Market Forecast Value (2023-2031)
4 Global Generic Drug Market Landscape
4.1 Global Generic Drug Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Generic Drug Product Landscape
4.2.1 Analysis by Brand
4.2.2 Analysis by Indications
4.2.3 Analysis by Route of Administration
5 Global Generic Drug Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Generic Drug Market Segmentation
6.1 Global Generic Drug Market by Brand
6.1.1 Market Overview
6.1.2 Pure Generic
6.1.3 Branded Generic
6.2 Global Generic Drug Market by Indications
6.2.1 Market Overview
6.2.2 Central Nervous System (CNS)
6.2.3 Cardiovascular
6.2.4 Dermatology
6.2.5 Oncology
6.2.6 Respiratory
6.2.7 Others
6.3 Global Generic Drug Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Topical
6.3.4 Parenteral
6.3.5 Others
6.4 Global Generic Drug Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Centers
6.4.5 Others
6.5 Global Generic Drug Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Online Pharmacy
6.5.4 Retail Pharmacy
6.6 Global Generic Drug Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Generic Drug Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Generic Drug Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Generic Drug Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Generic Drug Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Generic Drug Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Teva Pharmaceuticals Industries Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Mylan NV
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Sun Pharmaceutical Industries Ltd.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Fresenius SE & Co. KGaA
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Lupin
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Endo International plc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Aurobindo Pharma
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Novartis AG
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Hikma Pharmaceuticals PLC.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 STADA Arzneimittel AG
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Eli Lilly and Company
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Aspen Holdings
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Generic Drug Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security